Verex licensinq agreement
Executive Summary
Firm has licensed its Verexamil constant-release formulation of verapamil to "a subsidiary of a major European pharmaceutical group with 1984 sales of $1.2 bii." Verex said the agreement "includes an up-front licensing fee of $85,000 payable to Verex upon signing of the contract." Verex will also receive a worldwide license for the European company's currentiy marketed immediate-release verapamil formulations. . . .